FBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-28), Fortress Biotech's weighted average cost of capital is 12.67%%. Fortress Biotech's ROIC % is -173.64% (calculated using TTM income statement data). Fortress Biotech earns returns that do not match up to its cost of capital. It will destroy value as it grows.
For a comprehensive WACC calculation, please access the WACC Calculator.
The historical data trend for Fortress Biotech's WACC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortress Biotech Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
WACC % | Get a 7-Day Free Trial | 16.40 | 14.31 | 14.23 | 10.06 | 12.58 |
Fortress Biotech Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
WACC % | Get a 7-Day Free Trial | 10.06 | 11.22 | 12.74 | 12.97 | 12.58 |
For the Biotechnology subindustry, Fortress Biotech's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Fortress Biotech's WACC % distribution charts can be found below:
* The bar in red indicates where Fortress Biotech's WACC % falls into.
The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.
WACC | = | E | / | (E + D) | * | Cost of Equity | + | D | / | (E + D) | * | Cost of Debt | * | (1 - Tax Rate) |
1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Fortress Biotech's market capitalization (E) is $33.083 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Dec. 2023, Fortress Biotech's latest one-year quarterly average Book Value of Debt (D) is $97.135 Mil.
a) weight of equity = E / (E + D) = 33.083 / (33.083 + 97.135) = 0.2541
b) weight of debt = D / (E + D) = 97.135 / (33.083 + 97.135) = 0.7459
2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.663%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Fortress Biotech's beta is 1.53.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.663% + 1.53 * 6% = 13.843%
3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Dec. 2023, Fortress Biotech's interest expense (positive number) was $11.914 Mil. Its total Book Value of Debt (D) is $97.135 Mil.
Cost of Debt = 11.914 / 97.135 = 12.2654%.
4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0.52 / -153.634 = -0.34%, which is less than 0%. Therefore it's set to 0%.
Fortress Biotech's Weighted Average Cost Of Capital (WACC) for Today is calculated as:
WACC | = | E / (E + D) | * | Cost of Equity | + | D / (E + D) | * | Cost of Debt | * | (1 - Tax Rate) |
= | 0.2541 | * | 13.843% | + | 0.7459 | * | 12.2654% | * | (1 - 0%) | |
= | 12.67% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortress Biotech (NAS:FBIO) WACC % Explanation
Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Fortress Biotech's weighted average cost of capital is 12.67%%. Fortress Biotech's ROIC % is -173.64% (calculated using TTM income statement data). Fortress Biotech earns returns that do not match up to its cost of capital. It will destroy value as it grows.
1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.
2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.
3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
Rosenwald Lindsay A Md | director, 10 percent owner, officer: PRESIDENT, CEO & CHAIRMAN | 375 PARK AVE, NEW YORK NY 10152 |
Lucy Lu | director | THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137 |
David Jin | officer: Chief Financial Officer | C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036 |
Dov Klein | director | C/O FORTRESS BIOTECH, INC., 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019 |
Robyn Hunter | officer: Chief Financial Officer | 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453 |
Eric K Rowinsky | director | IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014 |
Malcolm Hoenlein | director | 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
Michael S Weiss | director, 10 percent owner, officer: EXECUTIVE VICE CHAIRMAN | 750 LEXINGTON AVE, NEW YORK NY 10022 |
J Jay Lobell | director | 365 W END AVE, APARTMENT 10A, NEW YORK NY 10024 |
Jimmie Harvey | director | 3741 EAST FAIRWAY DRIVE, BIRMINGHAM AL 35213 |
Kevin Lorenz | director | C/O NUVEEN, 333 W. WACKER DR., CHICAGO IL 60606 |
George Avgerinos | officer: SVP, Biologics Operations | C/O CORONADO BIOSCIENCES, INC., 24 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
Kevin Horgan | other: Former Chief Medical Officer | C/O SOLIGENIX, INC., 29 EMMONS DRIVE, STE. C-10, PRINCETON NJ 08540 |
David Jonathan Barrett | director | ONE PENN PLAZA, SUITE 2514, NEW YORK NY 10119 |
Harlan F Weisman | director | C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
From GuruFocus
By GuruFocus Research GuruFocus Editor • 10-24-2022
By sperokesalga sperokesalga • 02-15-2023
By Marketwired • 08-14-2023
By Stock market mentor Stock market mentor • 02-08-2023
By PRNewswire • 12-06-2023
By sperokesalga sperokesalga • 02-16-2023
By Marketwired • 10-05-2023
By GuruFocusNews GuruFocusNews • 07-10-2022
By GuruFocusNews GuruFocusNews • 06-27-2022
By PurpleRose PurpleRose • 07-22-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.